DR. PAUL ALFRED GURBEL, M.D.
Osteopathic Medicine at Belvedere Ave, Baltimore, MD
License number
Maryland D0034366
Category
Osteopathic Medicine
Type
Cardiovascular Disease
License number
Maryland D0034366
Category
Osteopathic Medicine
Type
Interventional Cardiology
Address
Address
2401 W Belvedere Ave, Baltimore, MD 21215
Phone
(410) 601-9600
(410) 601-9601 (Fax)
(410) 601-9601 (Fax)
Personal information
See more information about PAUL ALFRED GURBEL at radaris.comName
Address
Phone
Saint Michaels, MD
3813 Terka Cir, Randallstown, MD 21133
7862 Church Neck Rd, St Michaels, MD 21663
108 Saint Albans Way, Baltimore, MD 21212
8688 Liberty Rd, Randallstown, MD 21133
Professional information
Dr. Paul A Gurbel, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Cardiology, Interventional Cardiology
Address:
Paul A Gurbel MD
5051 Greenspring Ave SUITE 304, Baltimore 21209
(410) 601-9600 (Phone)
5051 Greenspring Ave SUITE 304, Baltimore 21209
(410) 601-9600 (Phone)
Certifications:
Cardiovascular Disease, 1989, Internal Medicine, 1986, Interventional Cardiology, 1999
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Paul A Gurbel MD
5051 Greenspring Ave SUITE 304, Baltimore 21209
Sinai Hospital of Baltimore
2401 West Belvedere Ave, Baltimore 21215
5051 Greenspring Ave SUITE 304, Baltimore 21209
Sinai Hospital of Baltimore
2401 West Belvedere Ave, Baltimore 21215
Education:
Medical School
University of Maryland At Baltimore / Professional Schools
Graduated: 1983
Duke University Hospital
Johns Hopkins
University of Maryland At Baltimore / Professional Schools
Graduated: 1983
Duke University Hospital
Johns Hopkins
Paul A Gurbel, Baltimore MD
Specialties:
Cardiologist
Address:
2401 W Belvedere Ave, Baltimore, MD 21215
Education:
University of Maryland, School of Medicine - Doctor of Medicine
Johns Hopkins Hospital - Fellowship - Pulmonary Disease (Internal Medicine)
Duke University Hospital - Fellowship - Cardiology
Duke University Hospital - Residency - Internal Medicine
Johns Hopkins Hospital - Fellowship - Pulmonary Disease (Internal Medicine)
Duke University Hospital - Fellowship - Cardiology
Duke University Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine), American Board of Internal Medicine Sub-certificate in Interventional Cardiology (Internal Medicine)
Methods Of Inhibiting Platelet Activation With Selective Serotonin Reuptake Inhibitors
US Patent:
6552014, Apr 22, 2003
Filed:
Mar 12, 2001
Appl. No.:
09/804689
Inventors:
Victor L. Serebruany - Ellicott City MD
Paul A. Gurbel - Baltimore MD
Christopher M. OConnor - Durham NC
Paul A. Gurbel - Baltimore MD
Christopher M. OConnor - Durham NC
Assignee:
HeartDrug Research, L.L.C. - Ellicott City MD
International Classification:
A61K 3155
US Classification:
51421402, 514217, 51425213, 51425405, 51425407, 514315, 514438, 514653, 514656, 514657
Abstract:
The present invention pertains to methods for reducing the platelet activation state in an individual comprising administering a selective serotonin reuptake inhibitor (SSRI). The platelet activation state is reduced upon administering a SSRI, as measured by one or more platelet activation markers. The invention also relates to methods for treating or preventing an individual at risk for a vascular event, disease or disorder by administering a SSRI.
Detection Of Restenosis Risk In Patients Receiving A Stent By Measuring The Characteristics Of Blood Clotting Including The Measurement Of Maximum Thrombin-Induced Clot Strength
US Patent:
8070678, Dec 6, 2011
Filed:
Oct 4, 2006
Appl. No.:
11/663599
Inventors:
Paul A. Gurbel - Baltimore MD, US
International Classification:
A61B 5/00
US Classification:
600369
Abstract:
A method of selecting a stent for implantation in the circulatory system of a human being includes the steps of determining a threshold level of platelet hyper-coaguability (PHC). One marker of PHC is platelet-fibrin mediated clot strength (MA) of blood. MA above a threshold demonstrates a risk of restenosis that is relatively high. In practicing the method, a sample of blood is obtained from a patient who requires implantation of a stent, the blood sample is tested for its platelet-fibrin mediated clot strength, the clot strength of the blood sample is compared with the threshold level; if the blood sample has a clot strength below the threshold level, selecting a bare metal stent, and if the blood sample has a clot strength at or above the threshold level, selecting a drug-eluting stent. The method includes, in a preferred embodiment, use of a viscoelastic monitor to perform the testing step. Other markers of PHC may also be employed such as measurement of thrombin generation and/or platelet reactivity.
Detection Of Restenosis Risk In Patients Receiving A Stent By Measuring The Characteristics Of Blood Clotting Including The Measurement Of Maximum Thrombin-Induced Clot Strength
US Patent:
2012026, Oct 18, 2012
Filed:
Dec 1, 2011
Appl. No.:
13/309121
Inventors:
Paul A. Gurbel - Baltimore MD, US
International Classification:
G01N 33/86, C12Q 1/56
US Classification:
435 13, 436 63
Abstract:
Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level. The determined platelet coagulability level of said blood sample is compared with a threshold level of blood platelet coagulability. A determined platelet coagulability level above said threshold level indicates that a risk of restenosis is relatively high. If the determined platelet coagulability level is below said threshold level, a bare metal stent is selected. If the determined platelet coagulability level is at or above said threshold level, a drug-eluting stent is selected.
Assessment Of Cardiac Health And Thrombotic Risk In A Patient
US Patent:
8440420, May 14, 2013
Filed:
Nov 7, 2011
Appl. No.:
13/290377
Inventors:
Paul A. Gurbel - Baltimore MD, US
International Classification:
C12Q 1/56
US Classification:
435 13, 435214, 435217
Abstract:
The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.
Determining A Treatment Plan For Patients Undergoing Thrombotic Event By Monitoring P-Selectin
US Patent:
6230713, May 15, 2001
Filed:
Jan 29, 1998
Appl. No.:
9/015385
Inventors:
Margaret R. Dalesandro - Devon PA
Paul A. Gurbel - Baltimore MD
Victor L. Serebruany - Ellicott City MD
Paul A. Gurbel - Baltimore MD
Victor L. Serebruany - Ellicott City MD
International Classification:
A61B 1900
US Classification:
128898
Abstract:
A treatment plan for patients suffering from a thrombotic event can be determined by measuring membrane bound and/or soluble P-selectin. The degree of reperfusion can be determined by assessing the level of soluble P-selectin subsequent to reperfusion. Additionally, predicting whether thrombolytic therapy will induce reperfusion can be determined by measuring the level of membrane bound P-selectin prior to reperfusion.
Methods Of Inhibiting Platelet Activation With Selective Serotonin Reuptake Inhibitors
US Patent:
6245782, Jun 12, 2001
Filed:
May 17, 1999
Appl. No.:
9/312987
Inventors:
Victor L. Serebruany - Ellicott City MD
Paul A. Gurbel - Baltimore MD
Christopher M. O'Connor - Durham NC
Paul A. Gurbel - Baltimore MD
Christopher M. O'Connor - Durham NC
Assignee:
Heartdrug Research L.L.C. - Ellicott City MD
International Classification:
A61K 31445, A61K 3134, A61K 3115, A61K 31135, A61K 3103
US Classification:
514321
Abstract:
The present invention pertains to methods for reducing the platelet activation state in an individual comprising administering a selective serotonin reuptake inhibitor (SSRI). The platelet activation state is reduced upon administering a SSRI, as measured by one or more platelet activation markers. The invention also relates to methods for treating or preventing an individual at risk for a vascular event, disease or disorder by administering a SSRI.
Autoperfusion Dilatation Catheter Having A Bonded Channel
US Patent:
5295959, Mar 22, 1994
Filed:
Mar 13, 1992
Appl. No.:
7/850638
Inventors:
Paul A. Gurbel - Baltimore MD
R. David Anderson - Baltimore MD
R. David Anderson - Baltimore MD
Assignee:
Medtronic, Inc. - Minneapolis MN
International Classification:
A61M 2900
US Classification:
604 96
Abstract:
An autoperfusion dilatation catheter useful in angioplasty comprises a conventional catheter shaft and an inflatable balloon. The catheter is designed such that the balloon, when inflated, has an outer surface relief-structure whereby when this outer surface is fully inflated and exerts pressure on the inner surface of a blood vessel, blood continues to flow between the outer surface of the balloon and the blood vessel surface. Preferably, the relief structure is a channel formed in the outer surface of the balloon by the pressure of a band attached to the catheter and which presses against the outer surface of the balloon.
Assessment Of Cardiac Health And Thrombotic Risk In A Patient
US Patent:
7381536, Jun 3, 2008
Filed:
Mar 1, 2005
Appl. No.:
11/070845
Inventors:
Paul A. Gurbel - Baltimore MD, US
International Classification:
C12Q 1/56
US Classification:
435 13
Abstract:
The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.